Keywords
Abstract
The aim of the study – to find out possible interactions of a potential anticonvulsant 5 [(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone with CNS stimulants and depressants and to analyze its possible mechanisms of action.
The experiments were performed on 66 white nonlinear mice. The test compound was administered intragastrically at a dose of 100 mg/kg. Interaction with caffeine sodium benzoate (20 mg/kg, intraperitoneally) was studied in an open field test. To assess the interaction with compounds of depressing action,
models of ethanol (12.5 %, intraperitoneally) and thiopental-induced anesthesia (70 mg/kg, intraperitoneally) were used. Piracetam was used as a reference drug at a dose of 400 mg/kg intragastrically.
In studying the interaction of 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone with caffeine sodium benzoate in a stimulating dose, a decrease in the stimulating effect was found: the locomotor activity of animals decreased by 42.55 % (p < 0.01) in comparison with the caffeine group, the sum
of all test parameters decreased by 33.33 % (p < 0.05). On the thiopental-induced anesthesia model, 5-[(Z)-(4-nitrobenzylidene)]-2- (thiazol-2-ylimino)-4-thiazolidinone did not potentiate the inhibitory effect of anesthesia. In studying the interaction with ethanol, a significant lengthening of the time spent by animals in the lateral position was found by 23.05 % compared with the control group (p < 0.05), which may indicate a pharmacodynamic interaction.
Thus, the absence of 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone potentiated interaction with barbiturates proved. Beneficial modulating influence on effects of caffeine was revealed.
No alcohol-protective activity was found in the test compound; on the contrary, it prolongs the anesthetic effect of ethanol. The results highlight the feasibility of further pharmacological studying the mechanism of action of 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylamino)-4-thiazolidinone.